Frovatriptan: pharmacological differences and clinical results

Area of Science:

• Pharmacology
• Neurology
• Clinical Trials

Background:

• Frovatriptan is a selective serotonin 5-HT(1B/1D) receptor agonist.
• It is used for acute migraine treatment.

Purpose of the Study:

• To evaluate the efficacy and tolerability of frovatriptan in migraine patients.
• To assess the pharmacokinetic profile of frovatriptan.

Main Methods:

• Three multicenter, double-blind, placebo-controlled phase III clinical trials were conducted.
• Patients received a 2.5 mg dose of frovatriptan or placebo.
• Headache response rates at 2 and 4 hours were primary endpoints.

Main Results:

• 2-hour headache response rates for frovatriptan ranged from 36-46% (vs. 21-27% for placebo).
• 4-hour headache response rates reached up to 65%.
• Frovatriptan demonstrated good tolerability, with adverse events only slightly higher than placebo.

Conclusions:

• Frovatriptan (2.5 mg) provides effective and rapid headache relief for migraineurs.
• The drug is well-tolerated and reduces associated migraine symptoms.
• Its long half-life contributes to prolonged relief and a low recurrence rate.